IL23R and inflammatory bowel disease: Of interest, genetic studies have highlighted components of the IL-23R response pathway significantly associated with a broad range of IMIDs, leading to novel understanding of the role of IL-23 in IMID pathogenesis, and contributed to the discovery of therapies targeting IL-23, currently licensed for use in psoriasis and IBD in the United Kingdom (Bianchi and Rogge, 2019).